Landos Biopharma

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Landos Biopharma is a developer of an oral first-in-class therapeutics designed to target autoimmune diseases.The company's therapeutics are novel, locally-acting small molecules targeting inflammatory bowel disease (IBD), crohn's disease (CD) and ulcerative colitis (UC), enabling healthcare providers to cure their patients.

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase an aggregate of 30,909,090 shares of its common stock at a price per pre-funded warrant of $0.54 to entities associated with Perceptive Advisors LLC, Landos' largest stockholder. The price per pre-funded warrant was based on the closing price per share of the Company's common stock on January 4, 2023. Gross proceeds from the financing total approximately $16.7 million, before deducting offering expenses. The closing of the financing is subject to customary closing conditions and is expected to close on or before January 10, 2023.

Landos Biopharma Announces $16.7 Million Private Placement Financing

Amyris

HTG Molecular Diagnostics

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals

Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

Angion Biomedica

Applied Therapeutics Inc

Bolt Biotherapeutics

Ikena Oncology

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Continued Progress Towards Optimizing Clinical Development Plans

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO

Landos Biopharma Announces Leadership Transition

Phase 1 trial is underway with topline results expected in the first half of 2022

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports. The peer-reviewed publication demonstrates omilancor's therapeutic efficacy in animal models of psoriasis.

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

Second Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine at Mount Sinai

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine. This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

Landos Biopharma to Participate in Upcoming Investor Events

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal  Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)

Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:00 AM EDT.

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

BeiGene

Burning Rock Biotech

Milestone Pharmaceuticals Inc

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben joins Landos with more than 20 years of executive experience leading development activities as well as successfully spearheading clinical and business strategies within the life sciences industry.

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and select Asian markets. Omilancor is a novel, oral, gut-restricted LANCL2 agonist in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and Eosinophilic Esophagitis (EoE).

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Completed initial public offering of common stock, raising approximately $100 million in gross proceeds

News for Landos Biopharma Stock (LABP)